{
  "resourceType": "StructureDefinition",
  "id": "oncology-BreastCancerPrognosticStage-model",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n  <p><b>BC BreastCancerPrognosticStage Logical Model</b></p>\n  <p>The prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.</p>\n</div>"
  },
  "url": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerPrognosticStage-model",
  "identifier": [
    {
      "system": "http://hl7.org/fhir/us/breastcancer",
      "value": "oncology.BreastCancerPrognosticStage"
    }
  ],
  "name": "BreastCancerPrognosticStage",
  "title": "BC BreastCancerPrognosticStage Logical Model",
  "status": "draft",
  "date": "2018-03-25",
  "publisher": "The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC).",
  "contact": [
    {
      "telecom": [
        {
          "system": "url",
          "value": "http://standardhealthrecord.org"
        }
      ]
    }
  ],
  "description": "The prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
  "keyword": [
    {
      "system": "http://loinc.org",
      "code": "21908-9"
    }
  ],
  "kind": "logical",
  "abstract": false,
  "type": "oncology-BreastCancerPrognosticStage-model",
  "baseDefinition": "http://hl7.org/fhir/StructureDefinition/Element",
  "derivation": "specialization",
  "snapshot": {
    "element": [
      {
        "id": "oncology-BreastCancerPrognosticStage-model",
        "path": "oncology-BreastCancerPrognosticStage-model",
        "definition": "The prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
        "min": 0,
        "max": "*",
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.value",
        "path": "oncology-BreastCancerPrognosticStage-model.value",
        "short": "Code representing the prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
        "definition": "Code representing the prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-BreastCancerStageVS"
          }
        }
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.topicCode",
        "path": "oncology-BreastCancerPrognosticStage-model.topicCode",
        "short": "The concept representing the finding or action that is the topic of the statement.",
        "definition": "The concept representing the finding or action that is the topic of the statement. \n\t\t\n\t\tFor action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding.\n\t\t\n\t\tThis attribute was named 'key' in CIMI V0.0.4. Recently, CIMI has recently moved to rename this element TopicCode, as anticipated here, to make it more clear that this is an identifier for the topic, not the context.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-TopicCode-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.findingMethod",
        "path": "oncology-BreastCancerPrognosticStage-model.findingMethod",
        "short": "The technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "definition": "The technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-FindingMethod-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.findingMethod.value",
        "path": "oncology-BreastCancerPrognosticStage-model.findingMethod.value",
        "short": "Code representing the technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "definition": "Code representing the technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-StagingMethodVS"
          }
        }
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.interpretation",
        "path": "oncology-BreastCancerPrognosticStage-model.interpretation",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0420833"
          }
        ],
        "short": "A clinical interpretation of a finding.",
        "definition": "A clinical interpretation of a finding.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-Interpretation-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.exceptionValue",
        "path": "oncology-BreastCancerPrognosticStage-model.exceptionValue",
        "short": "Reason that a value associated with a test or other finding is missing.",
        "definition": "Reason that a value associated with a test or other finding is missing.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-ExceptionValue-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.category",
        "path": "oncology-BreastCancerPrognosticStage-model.category",
        "short": "A class or division of people or things having particular shared characteristics",
        "definition": "A class or division of people or things having particular shared characteristics",
        "min": 1,
        "max": "*",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Category-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.category.value",
        "path": "oncology-BreastCancerPrognosticStage-model.category.value",
        "short": "Code representing a class or division of people or things having particular shared characteristics",
        "definition": "Code representing a class or division of people or things having particular shared characteristics",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "extensible",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/ValueSet/observation-category"
          }
        }
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.anatomicalLocation",
        "path": "oncology-BreastCancerPrognosticStage-model.anatomicalLocation",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C1545955"
          }
        ],
        "short": "A location or structure in the body, including tissues, regions, cavities, and spaces, for example, right elbow, or left ventricle of the heart.",
        "definition": "A location or structure in the body, including tissues, regions, cavities, and spaces, for example, right elbow, or left ventricle of the heart.\n\nNote: In CIMI Version 0.0.4, AnatomicalLocation has no parent class. This appears to have been an oversight, and the parent should have been Entity, as modeled here. This class corresponds to that CIMI reference model class, but it would be defined in a CIMI archetype, because it involves value set bindings on each of the attributes.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-AnatomicalLocation-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.specimen",
        "path": "oncology-BreastCancerPrognosticStage-model.specimen",
        "short": "Sample for analysis.",
        "definition": "Sample for analysis. \n\nNOTE: This class has been cut down to separate it from other parts of the reference model that are not relevant to the current oncology ballot.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-Specimen-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.deltaFlag",
        "path": "oncology-BreastCancerPrognosticStage-model.deltaFlag",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C1705241"
          }
        ],
        "short": "Indicator of significant change (delta) from the last or previous measurement.",
        "definition": "Indicator of significant change (delta) from the last or previous measurement.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-DeltaFlag-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.precondition",
        "path": "oncology-BreastCancerPrognosticStage-model.precondition",
        "short": "A description of the conditions or context of an observation, for example, under sedation, fasting or post-exercise.",
        "definition": "A description of the conditions or context of an observation, for example, under sedation, fasting or post-exercise. \n\t\t\n\t\tBody position and body site are also qualifiers, but handled separately. A qualifier cannot modify the measurement type; for example, a fasting blood sugar is still a blood sugar.",
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-Precondition-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.referenceRange",
        "path": "oncology-BreastCancerPrognosticStage-model.referenceRange",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0883335"
          }
        ],
        "short": "The usual or acceptable range for a test result.",
        "definition": "The usual or acceptable range for a test result.",
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-ReferenceRange-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent",
        "short": "A simplified, non-separable evaluation consisting of a finding code (represented by the Concept), value (or exception value), reference range, and interpretation.",
        "definition": "A simplified, non-separable evaluation consisting of a finding code (represented by the Concept), value (or exception value), reference range, and interpretation. \n\t\t\n\t\tThe subject of the evaluation component is the same as in the parent evaluation.",
        "min": 1,
        "max": "1",
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerTCategory",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerTCategory",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "78873005",
            "display": "T category"
          }
        ],
        "short": "The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer.",
        "definition": "The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerTCategory-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerNCategory",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerNCategory",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "277206009",
            "display": "N category"
          }
        ],
        "short": "The presence of metastases in regional lymph nodes. The node category for staging is based on criteria from the American Joint Committee on Cancer.",
        "definition": "The presence of metastases in regional lymph nodes. The node category for staging is based on criteria from the American Joint Committee on Cancer.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerNCategory-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerMCategory",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerMCategory",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "126926005",
            "display": "M category"
          }
        ],
        "short": "Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body.",
        "definition": "Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerMCategory-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.recordedContext",
        "path": "oncology-BreastCancerPrognosticStage-model.recordedContext",
        "short": "Context for an evaluation result, used to indicate an evaluation has been made.",
        "definition": "Context for an evaluation result, used to indicate an evaluation has been made. \n\t\n\tFor example, measurement of blood pressure that has been made simply exists (although the value can be present or absent, accurate or inaccurate). The RecordedContext indicates the information presented stands on its own as presented. It can also apply to a clinical notes.\n\t\n\tThe RecordedContext class did not exist in CIMI Version 0.0.4, but CIMI is the process of adding it. That change is anticipated here.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-RecordedContext-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members",
        "path": "oncology-BreastCancerPrognosticStage-model.members",
        "short": "Members represent the elements of a group of a related but independent evaluations.",
        "definition": "Members represent the elements of a group of a related but independent evaluations. \n\t\t\n\t\tExamples are the measurements that compose a complete blood count (CBC), or the elements of a pathology report. Each member is an independent evaluation, but the grouping reflects a composite lab order, shared specimen, or a single report author. Typically the Category and Reason are not given for individual findings that are part of the panel, but rather given at the level of the panel itself.\n\t\t\n\t\tCIMI V0.0.4 does not have this attribute.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "BackboneElement"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value",
        "short": "EvaluationResultRecorded representing members represent the elements of a group of a related but independent evaluations.",
        "definition": "EvaluationResultRecorded representing members represent the elements of a group of a related but independent evaluations. \n\t\t\n\t\tExamples are the measurements that compose a complete blood count (CBC), or the elements of a pathology report. Each member is an independent evaluation, but the grouping reflects a composite lab order, shared specimen, or a single report author. Typically the Category and Reason are not given for individual findings that are part of the panel, but rather given at the level of the panel itself.\n\t\t\n\t\tCIMI V0.0.4 does not have this attribute.",
        "alias": [
          "evaluationResultRecorded"
        ],
        "min": 1,
        "max": "1",
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.hER2ReceptorStatus",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.hER2ReceptorStatus",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "48676-1",
            "display": "HER2 [Interpretation] in Tissue"
          }
        ],
        "short": "HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.",
        "definition": "HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.\n\nWe are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence from HER2 by IHC and/or HER2 by ISH tests, not a direct observation.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-HER2ReceptorStatus-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.estrogenReceptorStatus",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.estrogenReceptorStatus",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "16112-5",
            "display": "Estrogen receptor [Interpretation] in Tissue"
          }
        ],
        "short": "Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.",
        "definition": "Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.\n\nWe are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence (NuclearPositivity and AverageStainingIntensity).",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-EstrogenReceptorStatus-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.progesteroneReceptorStatus",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.progesteroneReceptorStatus",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "16113-3"
          }
        ],
        "short": "Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity.",
        "definition": "Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity. \n\nBased on discussion with Cancer Interoperability Group subject matter experts, there was insufficient rationale to include the following components in the data model: StainingControl, PrimaryAntibody, Allred Score (both total and component scores). We are seeking feedback on whether or not those components should be included in this model.\n\nWe are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence (NuclearPositivity and AverageStainingIntensity).",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-ProgesteroneReceptorStatus-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.nuclearGrade",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.nuclearGrade",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C18513"
          }
        ],
        "short": "An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade.",
        "definition": "An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-NuclearGrade-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.histologicGrade",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.histologicGrade",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "44648-4"
          }
        ],
        "short": "The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing.",
        "definition": "The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-HistologicGrade-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.stageTimingPrefix",
        "path": "oncology-BreastCancerPrognosticStage-model.stageTimingPrefix",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "260869008",
            "display": "Timing of stage"
          }
        ],
        "short": "Mandatory element indicating when the staging was done, in terms of treatment landmarks, either clinical (at diagnosis prior to treatment) (c), pathologic (post-surgical) (p), post-neoadjuvant clinical (yc), or post-neoadjuvant pathologic(yp). The stage timing code is prefix on the N stage. For example, for post-neoadjuvant clinical staging, the N categories are preceded by 'yc' (e.g. ycNX)",
        "definition": "Mandatory element indicating when the staging was done, in terms of treatment landmarks, either clinical (at diagnosis prior to treatment) (c), pathologic (post-surgical) (p), post-neoadjuvant clinical (yc), or post-neoadjuvant pathologic(yp). The stage timing code is prefix on the N stage. For example, for post-neoadjuvant clinical staging, the N categories are preceded by 'yc' (e.g. ycNX)",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-StageTimingPrefix-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      }
    ]
  },
  "differential": {
    "element": [
      {
        "id": "oncology-BreastCancerPrognosticStage-model",
        "path": "oncology-BreastCancerPrognosticStage-model",
        "definition": "The prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
        "min": 0,
        "max": "*",
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.value",
        "path": "oncology-BreastCancerPrognosticStage-model.value",
        "short": "Code representing the prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
        "definition": "Code representing the prognostic stage of a breast cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). Only the prognostic stage is used in US and Canada.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-BreastCancerStageVS"
          }
        }
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.topicCode",
        "path": "oncology-BreastCancerPrognosticStage-model.topicCode",
        "short": "The concept representing the finding or action that is the topic of the statement.",
        "definition": "The concept representing the finding or action that is the topic of the statement. \n\t\t\n\t\tFor action topics, the TopicCode represents the action being described. For findings, the TopicCode represents the 'question' or property being investigated. For evaluation result findings, the TopicCode contains a concept for an observable entity, such as systolic blood pressure. For assertion findings, the TopicCode contains a code representing the condition, allergy, or other item being asserted. In all cases, the TopicCode describes the topic independent of the context of the action or the finding.\n\t\t\n\t\tThis attribute was named 'key' in CIMI V0.0.4. Recently, CIMI has recently moved to rename this element TopicCode, as anticipated here, to make it more clear that this is an identifier for the topic, not the context.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-TopicCode-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.findingMethod",
        "path": "oncology-BreastCancerPrognosticStage-model.findingMethod",
        "short": "The technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "definition": "The technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-FindingMethod-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.findingMethod.value",
        "path": "oncology-BreastCancerPrognosticStage-model.findingMethod.value",
        "short": "Code representing the technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "definition": "Code representing the technique used to create the finding, for example, the specific imaging technical, lab test code, or assessment vehicle. In CIMI Version 0.0.4, this attribute is called 'method'.",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "required",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-StagingMethodVS"
          }
        }
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.interpretation",
        "path": "oncology-BreastCancerPrognosticStage-model.interpretation",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0420833"
          }
        ],
        "short": "A clinical interpretation of a finding.",
        "definition": "A clinical interpretation of a finding.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-Interpretation-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.exceptionValue",
        "path": "oncology-BreastCancerPrognosticStage-model.exceptionValue",
        "short": "Reason that a value associated with a test or other finding is missing.",
        "definition": "Reason that a value associated with a test or other finding is missing.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-ExceptionValue-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.category",
        "path": "oncology-BreastCancerPrognosticStage-model.category",
        "short": "A class or division of people or things having particular shared characteristics",
        "definition": "A class or division of people or things having particular shared characteristics",
        "min": 1,
        "max": "*",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/shr-core-Category-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.category.value",
        "path": "oncology-BreastCancerPrognosticStage-model.category.value",
        "short": "Code representing a class or division of people or things having particular shared characteristics",
        "definition": "Code representing a class or division of people or things having particular shared characteristics",
        "alias": [
          "codeableConcept"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Coding"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false,
        "binding": {
          "strength": "extensible",
          "valueSetReference": {
            "reference": "http://hl7.org/fhir/ValueSet/observation-category"
          }
        }
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.anatomicalLocation",
        "path": "oncology-BreastCancerPrognosticStage-model.anatomicalLocation",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C1545955"
          }
        ],
        "short": "A location or structure in the body, including tissues, regions, cavities, and spaces, for example, right elbow, or left ventricle of the heart.",
        "definition": "A location or structure in the body, including tissues, regions, cavities, and spaces, for example, right elbow, or left ventricle of the heart.\n\nNote: In CIMI Version 0.0.4, AnatomicalLocation has no parent class. This appears to have been an oversight, and the parent should have been Entity, as modeled here. This class corresponds to that CIMI reference model class, but it would be defined in a CIMI archetype, because it involves value set bindings on each of the attributes.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-AnatomicalLocation-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.specimen",
        "path": "oncology-BreastCancerPrognosticStage-model.specimen",
        "short": "Sample for analysis.",
        "definition": "Sample for analysis. \n\nNOTE: This class has been cut down to separate it from other parts of the reference model that are not relevant to the current oncology ballot.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-Specimen-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.deltaFlag",
        "path": "oncology-BreastCancerPrognosticStage-model.deltaFlag",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C1705241"
          }
        ],
        "short": "Indicator of significant change (delta) from the last or previous measurement.",
        "definition": "Indicator of significant change (delta) from the last or previous measurement.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-DeltaFlag-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.precondition",
        "path": "oncology-BreastCancerPrognosticStage-model.precondition",
        "short": "A description of the conditions or context of an observation, for example, under sedation, fasting or post-exercise.",
        "definition": "A description of the conditions or context of an observation, for example, under sedation, fasting or post-exercise. \n\t\t\n\t\tBody position and body site are also qualifiers, but handled separately. A qualifier cannot modify the measurement type; for example, a fasting blood sugar is still a blood sugar.",
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-Precondition-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.referenceRange",
        "path": "oncology-BreastCancerPrognosticStage-model.referenceRange",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C0883335"
          }
        ],
        "short": "The usual or acceptable range for a test result.",
        "definition": "The usual or acceptable range for a test result.",
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-ReferenceRange-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent",
        "short": "A simplified, non-separable evaluation consisting of a finding code (represented by the Concept), value (or exception value), reference range, and interpretation.",
        "definition": "A simplified, non-separable evaluation consisting of a finding code (represented by the Concept), value (or exception value), reference range, and interpretation. \n\t\t\n\t\tThe subject of the evaluation component is the same as in the parent evaluation.",
        "min": 1,
        "max": "1",
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerTCategory",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerTCategory",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "78873005",
            "display": "T category"
          }
        ],
        "short": "The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer.",
        "definition": "The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerTCategory-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerNCategory",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerNCategory",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "277206009",
            "display": "N category"
          }
        ],
        "short": "The presence of metastases in regional lymph nodes. The node category for staging is based on criteria from the American Joint Committee on Cancer.",
        "definition": "The presence of metastases in regional lymph nodes. The node category for staging is based on criteria from the American Joint Committee on Cancer.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerNCategory-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerMCategory",
        "path": "oncology-BreastCancerPrognosticStage-model.evaluationComponent.breastCancerMCategory",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "126926005",
            "display": "M category"
          }
        ],
        "short": "Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body.",
        "definition": "Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-BreastCancerMCategory-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.recordedContext",
        "path": "oncology-BreastCancerPrognosticStage-model.recordedContext",
        "short": "Context for an evaluation result, used to indicate an evaluation has been made.",
        "definition": "Context for an evaluation result, used to indicate an evaluation has been made. \n\t\n\tFor example, measurement of blood pressure that has been made simply exists (although the value can be present or absent, accurate or inaccurate). The RecordedContext indicates the information presented stands on its own as presented. It can also apply to a clinical notes.\n\t\n\tThe RecordedContext class did not exist in CIMI Version 0.0.4, but CIMI is the process of adding it. That change is anticipated here.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/cimi-RecordedContext-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members",
        "path": "oncology-BreastCancerPrognosticStage-model.members",
        "short": "Members represent the elements of a group of a related but independent evaluations.",
        "definition": "Members represent the elements of a group of a related but independent evaluations. \n\t\t\n\t\tExamples are the measurements that compose a complete blood count (CBC), or the elements of a pathology report. Each member is an independent evaluation, but the grouping reflects a composite lab order, shared specimen, or a single report author. Typically the Category and Reason are not given for individual findings that are part of the panel, but rather given at the level of the panel itself.\n\t\t\n\t\tCIMI V0.0.4 does not have this attribute.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "BackboneElement"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value",
        "short": "EvaluationResultRecorded representing members represent the elements of a group of a related but independent evaluations.",
        "definition": "EvaluationResultRecorded representing members represent the elements of a group of a related but independent evaluations. \n\t\t\n\t\tExamples are the measurements that compose a complete blood count (CBC), or the elements of a pathology report. Each member is an independent evaluation, but the grouping reflects a composite lab order, shared specimen, or a single report author. Typically the Category and Reason are not given for individual findings that are part of the panel, but rather given at the level of the panel itself.\n\t\t\n\t\tCIMI V0.0.4 does not have this attribute.",
        "alias": [
          "evaluationResultRecorded"
        ],
        "min": 1,
        "max": "1",
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.hER2ReceptorStatus",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.hER2ReceptorStatus",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "48676-1",
            "display": "HER2 [Interpretation] in Tissue"
          }
        ],
        "short": "HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.",
        "definition": "HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.\n\nWe are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence from HER2 by IHC and/or HER2 by ISH tests, not a direct observation.",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-HER2ReceptorStatus-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.estrogenReceptorStatus",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.estrogenReceptorStatus",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "16112-5",
            "display": "Estrogen receptor [Interpretation] in Tissue"
          }
        ],
        "short": "Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.",
        "definition": "Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.\n\nWe are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence (NuclearPositivity and AverageStainingIntensity).",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-EstrogenReceptorStatus-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.progesteroneReceptorStatus",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.progesteroneReceptorStatus",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "16113-3"
          }
        ],
        "short": "Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity.",
        "definition": "Progesterone receptor status is a factor in determining prognosis and treatment options. The value is the percentage of cells that test (stain) positive for the presence of a receptor. The interpretation of positive or negative (found in the interpretation property) is based on the staining percentage, and may take into account the staining intensity. \n\nBased on discussion with Cancer Interoperability Group subject matter experts, there was insufficient rationale to include the following components in the data model: StainingControl, PrimaryAntibody, Allred Score (both total and component scores). We are seeking feedback on whether or not those components should be included in this model.\n\nWe are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The current approach is that positive/negative designation is a value, even though that value is (in fact) an interpretation of evidence (NuclearPositivity and AverageStainingIntensity).",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-ProgesteroneReceptorStatus-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.nuclearGrade",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.nuclearGrade",
        "code": [
          {
            "system": "http://ncimeta.nci.nih.gov",
            "code": "C18513"
          }
        ],
        "short": "An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade.",
        "definition": "An evaluation of the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are in the process of dividing or growing. Cancers with low nuclear grade grow and spread less quickly than cancers with high nuclear grade.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-NuclearGrade-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.members.value.histologicGrade",
        "path": "oncology-BreastCancerPrognosticStage-model.members.value.histologicGrade",
        "code": [
          {
            "system": "http://loinc.org",
            "code": "44648-4"
          }
        ],
        "short": "The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing.",
        "definition": "The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing.",
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "Reference",
            "targetProfile": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-HistologicGrade-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      },
      {
        "id": "oncology-BreastCancerPrognosticStage-model.stageTimingPrefix",
        "path": "oncology-BreastCancerPrognosticStage-model.stageTimingPrefix",
        "code": [
          {
            "system": "http://snomed.info/sct",
            "code": "260869008",
            "display": "Timing of stage"
          }
        ],
        "short": "Mandatory element indicating when the staging was done, in terms of treatment landmarks, either clinical (at diagnosis prior to treatment) (c), pathologic (post-surgical) (p), post-neoadjuvant clinical (yc), or post-neoadjuvant pathologic(yp). The stage timing code is prefix on the N stage. For example, for post-neoadjuvant clinical staging, the N categories are preceded by 'yc' (e.g. ycNX)",
        "definition": "Mandatory element indicating when the staging was done, in terms of treatment landmarks, either clinical (at diagnosis prior to treatment) (c), pathologic (post-surgical) (p), post-neoadjuvant clinical (yc), or post-neoadjuvant pathologic(yp). The stage timing code is prefix on the N stage. For example, for post-neoadjuvant clinical staging, the N categories are preceded by 'yc' (e.g. ycNX)",
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "http://hl7.org/fhir/us/breastcancer/StructureDefinition/oncology-StageTimingPrefix-model"
          }
        ],
        "mustSupport": false,
        "isModifier": false,
        "isSummary": false
      }
    ]
  }
}